Lupin collaborates with AbbVie for $977m MALT1 inhibitor program targeting hematological cancers
Indian pharmaceutical company Lupin has entered a landmark agreement to out-license its MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program to US-based biopharmaceutical giant AbbVie. The deal, potentially worth $977 million, grants AbbVie exclusive global rights to develop and commercialize the novel inhibitors. Key highlights of the deal Under the terms of the […]